The present invention provides a time and space adjustable system for inhibiting pathological target cells. The system comprises: (1) fusion protein, comprising polypeptide tags and binding molecules for specifically recognizing pathological target cells； and (2) chimeric antigen receptor immune effector cells, which express binding molecules for specifically recognizing the polypeptide tags. Disclosed is a technical solution based on a tumor-specific chimeric antigen receptor (CAR) technology, in which the immune effector cells can target pathological target cells only in the presence of a mediator, and the CAR immune effector cells can expand continuously and have killing effect on tumor cells； the CAR immune effector cells have no effect in the absence of a mediator.
